THURSDAY, Jan. 18, 2024 -- For adults with mild-to-moderate COVID-19, early administration of simnotrelvir plus ritonavir shortens the time to sustained resolution of symptoms, according to a study published in the Jan. 18 issue of the New England Journal of Medicine. The researchers found that the time to sustained resolution of COVID-19 symptoms was significantly shorter in the simnotrelvir group than the placebo group (180.1 versus 216.0 hours) among patients in the modified intention-to-treat population. The decrease in viral load from baseline was greater in the simnotrelvir group than in the placebo group on day 5 (mean difference, −1.51 ± 0.14 log10 copies/mL). A higher incidence of adverse events during treatment was seen in the simnotrelvir group versus placebo group (29.0 versus 21.6 percent); most of the adverse events were mild or moderate. "Early administration of simnotrelvir plus ritonavir was effective in shortening the time to symptom resolution among adult patients with COVID-19, without evident safety concerns," the authors write. Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Further Support and Information on COVID-19 COVID-19: Prevention & Investigational Treatments Coronavirus Disease Guide
News for Health Professionals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.